During the menopause transition, fat mass rises faster and lean mass starts to decline, even when the scale moves only slowly. Hormone therapy treats menopausal symptoms rather than weight, while GLP-1 medications, strength training and protein address weight and body composition.
Weight and body shape often change around menopause, but the biggest shift is in body composition rather than the number on the scale. A long-running NIH-funded study found that at the start of the menopause transition, the rate of fat gain roughly doubles and lean mass begins to decline, while overall weight keeps climbing at about the same slow pace as before. Hormone therapy is used to treat menopausal symptoms, not weight. GLP-1 medications, strength training and adequate protein are the tools aimed at weight and body composition, and some people use both approaches under a clinician's care.
The National Institute on Aging (NIA) explains that most women begin the menopausal transition between ages 45 and 55, that it can last several years, and that the average age of menopause in the US is 52. During the transition, production of estrogen and progesterone by the ovaries declines greatly. NIA also notes that the body begins to use energy differently, the distribution of fat changes, and women may gain weight more easily, along with possible changes in bone density, heart health and physical function.
The most detailed picture comes from the Study of Women's Health Across the Nation (SWAN), which tracked women through midlife with body composition scans. A 2019 analysis in JCI Insight found:
| Measure | Before the transition | During the transition | After the transition |
|---|---|---|---|
| Fat mass | Rising about 1.0% per year | Rising about 1.7% per year | Leveling off |
| Lean mass | Rising about 0.2% per year | Falling about 0.2% per year | Leveling off |
| Body weight | Rising slowly | Rising at a similar pace | Leveling off |
Over the roughly 3.5-year transition, the average participant's fat mass rose about 6 percent while lean mass fell slightly. Gains and losses continued until about 2 years after the final menstrual period, and then the trajectories flattened. Because fat was going up while lean tissue was going down, total weight did not visibly speed up, even though the body underneath was changing.
That finding helps explain a common experience: clothes fit differently, or the waistline changes, while the scale suggests little has happened.
The SWAN authors concluded that the accelerated gain in fat mass and loss of lean mass are phenomena of the menopause transition itself. NIA links many menopausal changes to the decline in estrogen and progesterone. NIA also lists trouble sleeping, night sweats, joint and muscle discomfort, and moodiness among the symptoms some women experience during the transition. These are worth discussing in their own right, because they shape daily routines.
Hormone therapy is a treatment for menopausal symptoms. In its announcements about menopausal hormone therapy labeling, the FDA describes it as relieving symptoms such as hot flashes, night sweats, sleep disturbances and bone loss. Weight management is not among its stated purposes.
The North American Menopause Society (now The Menopause Society) said in its 2022 position statement that hormone therapy remains the most effective treatment for hot flashes and genitourinary symptoms and has been shown to prevent bone loss and fracture. For women younger than 60 or within 10 years of menopause onset without contraindications, it described the benefit-risk ratio as favorable for bothersome hot flashes and prevention of bone loss.
The regulatory picture has also changed. In November 2025 the FDA announced it would remove broad boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, while keeping the boxed warning about endometrial cancer for systemic estrogen-alone products. In February 2026 it approved the first labeling changes for six products. The FDA's labeled recommendation for systemic therapy is to start within 10 years of menopause onset or before age 60. For more detail on options, see our guide to perimenopause and menopause hormone therapy.
GLP-1 medications such as semaglutide and tirzepatide are weight-management medications; they do not treat hot flashes or other menopausal symptoms. Our guide on how GLP-1 medications work explains the mechanism.
Can the two approaches work together? A 2024 study in the journal Menopause reviewed records of 106 postmenopausal women treated with semaglutide at Mayo Clinic, 16 of whom were using hormone therapy. At 12 months, average total body weight loss was 16 percent in the hormone therapy group and 12 percent in the group not using it, and the difference held after adjusting for other factors. The authors were clear about the limits: the study was small and retrospective, so it cannot show that hormone therapy caused the difference, and larger prospective studies are needed. Individual results vary widely.
It is also worth remembering that weight loss usually includes some lean tissue. In a 2017 New England Journal of Medicine trial in older adults with obesity, lean mass declined in every weight-loss group, least when resistance training was part of the plan. Because lean mass is already trending down during the menopause transition, protecting muscle deserves extra attention if you are using a GLP-1 medication in midlife.
On average, SWAN found that weight rose steadily through midlife without a clear speed-up at the transition. What did change was body composition: fat gain accelerated and lean mass began to decline. Many women notice this as a change in shape or waistline rather than a jump on the scale.
Hormone therapy is used to treat menopausal symptoms such as hot flashes, night sweats and bone loss, not as a weight-loss treatment. One small study found women on hormone therapy lost more weight with semaglutide, but it was observational and cannot prove cause and effect. A licensed provider can explain what hormone therapy can and cannot be expected to do for you.
Some people do use both under a prescriber's care, and the 2024 Menopause study looked at women who were on both. Each medication has its own considerations, so your clinician will review your history, other medications and goals. Prescribing decisions and dosing are made by your provider.
The Physical Activity Guidelines recommend muscle-strengthening activity for adults and include specific guidance for older adults. Starting with lighter loads and good form is reasonable, and if you have joint problems or osteoporosis, ask your clinician which exercises fit.
Midlife weight changes have several causes, and the right plan depends on your symptoms, health history and goals. A licensed provider can help you decide whether symptom treatment, weight treatment, or both make sense, and how to protect muscle and bone along the way. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
GLP-1 results vary widely. In trials, most people reached at least 5 percent weight loss while a minority did not. Medication and dose, type 2 diabetes, staying on treatment and early response all help explain the spread.
Read article
You can travel, celebrate and eat out on a GLP-1 medication with some planning: keep medication in your carry-on and follow your pharmacy's storage instructions, order smaller portions, keep fluids up, and ask your prescriber how to handle timing changes.
Read article
An underactive thyroid can add modest weight and fatigue, so a TSH test is a sensible check if you have symptoms. Separately, GLP-1 labels warn against use with a personal or family history of medullary thyroid cancer or MEN 2, so share your full thyroid history.
Read article